- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Pleasanton Today
By the People, for the People
JPMorgan Chase Significantly Boosts Stake in 10x Genomics
The financial giant increased its position in the biotech company by over 777% in the third quarter.
Mar. 28, 2026 at 8:59am
Got story updates? Submit your updates here. ›
JPMorgan Chase & Co. grew its position in shares of 10x Genomics (NASDAQ:TXG) by 777.6% during the third quarter, according to the company's recent disclosure with the Securities & Exchange Commission. The fund now owns over 1 million shares of the biotech company, worth $12.6 million, representing 0.85% ownership.
Why it matters
This significant increase in JPMorgan's stake in 10x Genomics signals the financial institution's confidence in the biotech firm's growth potential. As a major player in the market, JPMorgan's investment decisions can influence investor sentiment and the stock's performance.
The details
According to the filing, JPMorgan Chase added 951,495 shares of 10x Genomics during the third quarter, bringing its total position to 1,073,865 shares. This represents a 777.6% increase from the previous quarter. Other major institutional investors, including AQR Capital Management, Millennium Management, and Wellington Management, also boosted their stakes in 10x Genomics during the same period.
- JPMorgan Chase disclosed the increased stake in its 13F filing for the third quarter of 2026.
- The filing was submitted on March 28, 2026.
The players
JPMorgan Chase & Co.
A multinational investment bank and financial services company headquartered in New York City.
10x Genomics
A biotechnology company that develops and manufactures integrated hardware, consumables, and software products for single-cell sequencing and spatial genomics.
The takeaway
The surge in JPMorgan Chase's investment in 10x Genomics underscores the financial institution's belief in the biotech firm's ability to capitalize on the growing demand for advanced genomic analysis solutions. This move could signal increased investor interest and potential future growth for 10x Genomics.
